STTK Shattuck Labs
- 11.150
- +0.050+0.45%
Shattuck Labs News
Buy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154
Express News | HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $28 Price Target
Shattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical Milestones
Express News | Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Express News | Shattuck Labs: Cash, Equivalents, Investments to Be Sufficient to Fund Ops Into 2026, Beyond Results From Phase 1 Clinical Trials of Sl-172154
Express News | Shattuck Labs Q1 Collaboration Revenue USD 1.115 Million
Express News | Shattuck Labs Q1 Net Income USD -18.504 Million
Express News | Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Express News | Shattuck Labs Q1 Basic EPS USD -0.37
Express News | Shattuck Labs Q1 Income From Operations USD -20.044 Million
Shattuck Labs 1Q Loss/Shr 37c >STTK
Shattuck Labs 1Q Loss/Shr 37c >STTK
28% Of This Shattuck Labs Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Shattuck Labs, Inc.'s (NASDAQ:STTK ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. Althou
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)
Express News | Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1
Express News | Needham Reiterates Buy on Shattuck Labs, Maintains $12 Price Target
Strong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and Leadership
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Shattuck Labs (NASDAQ:STTK) has seen its share price rise 227% over the last year, deli
Analysis
Price Target
No Data
